Office of Drug Evaluation IV, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
PedMed Consulting, Chapel Hill, NC, USA.
J Clin Pharmacol. 2019 Sep;59 Suppl 1:S9-S20. doi: 10.1002/jcph.1490.
The clinical applications of renal ontogeny mainly include renal function evaluation and optimal dosing of renally eliminated drugs in pediatric patients, which rely on pharmacometric models and/or bedside estimated glomerular filtration rate equations. However, these applications in drug development are based on an understanding of renal function development, especially when considering premature infants, and the renal biomarkers that can be used for renal function assessment. This review provides a general overview on (1) renal function development, (2) the biomarkers that are used to assess renal function, and (3) the practical application of this knowledge to drug dosing for renally eliminated drugs during pediatric development. While pharmacometric approaches for estimating renal function during development have improved considerably, the number of drug development programs that have studied premature infants is small and suggests that caution should be taken in estimating doses for renally eliminated drugs during periods of rapid change in renal function.
肾脏发生学的临床应用主要包括肾功能评估和儿科患者肾清除药物的最佳剂量,这依赖于药代动力学模型和/或床旁估算肾小球滤过率方程。然而,药物开发中的这些应用是基于对肾功能发育的理解,特别是在考虑早产儿时,以及可用于肾功能评估的肾脏生物标志物。这篇综述提供了一个关于(1)肾功能发育、(2)用于评估肾功能的生物标志物、(3)将这些知识应用于儿科发育期间肾清除药物的药物剂量的一般概述。虽然在发育过程中估算肾功能的药代动力学方法已经有了很大的改进,但研究早产儿的药物开发项目数量很少,这表明在肾功能快速变化期间,估算肾清除药物的剂量时应谨慎。